Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...